It is unknown whether the addition of antithymocyte globulin (ATG) to reduced-intensity conditioning with busulfan (BU) and fludarabine (FLU) is beneficial in HLA-identical sibling transplantation. Therefore, we analyzed retrospectively data on 83 patients, who received peripheral blood stem cells from HLA-identical siblings after conditioning with either 8 mg/kg BU and 150 mg/m 2 FLU (n ¼ 45) or 8 mg/kg BU, 180 mg/m 2 FLU and 40 mg/ kg ATG (n ¼ 38). Graft-versus-host disease (GVHD) prophylaxis consisted of CSA alone (n ¼ 32) or a combination with either MTX or MMF (n ¼ 51). The median age was 52 years. Graft failure occurred in two patients after BU/FLU and in three after BU/FLU/ATG (P ¼ 0.66). After conditioning with BU/FLU, platelet recovery was significantly faster (P ¼ 0.017), and less platelet (Po0.001) and red blood cell (P ¼ 0.002) support was needed. Incidences of acute GVHD grades II and IV were 46 and 49%, respectively. Limited chronic GVHD occurred more often after BU/FLU compared to BU/FLU/ ATG (54 vs 23%, P ¼ 0.02). The overall survival, nonrelapse and relapse mortality did not differ significantly. We conclude that in peripheral blood stem cell transplantation from HLA-identical siblings after reduced-intensity conditioning with BU and FLU, ATG has no major impact on the rate of graft rejection and acute GVHD, but it reduces the incidence of limited chronic GVHD.
Summary:
It is unknown whether the addition of antithymocyte globulin (ATG) to reduced-intensity conditioning with busulfan (BU) and fludarabine (FLU) is beneficial in HLA-identical sibling transplantation. Therefore, we analyzed retrospectively data on 83 patients, who received peripheral blood stem cells from HLA-identical siblings after conditioning with either 8 mg/kg BU and 150 mg/m 2 FLU (n ¼ 45) or 8 mg/kg BU, 180 mg/m 2 FLU and 40 mg/ kg ATG (n ¼ 38). Graft-versus-host disease (GVHD) prophylaxis consisted of CSA alone (n ¼ 32) or a combination with either MTX or MMF (n ¼ 51). The median age was 52 years. Graft failure occurred in two patients after BU/FLU and in three after BU/FLU/ATG (P ¼ 0.66). After conditioning with BU/FLU, platelet recovery was significantly faster (P ¼ 0.017), and less platelet (Po0.001) and red blood cell (P ¼ 0.002) support was needed. Incidences of acute GVHD grades II and IV were 46 and 49%, respectively. Limited chronic GVHD occurred more often after BU/FLU compared to BU/FLU/ ATG (54 vs 23%, P ¼ 0.02). The overall survival, nonrelapse and relapse mortality did not differ significantly. We conclude that in peripheral blood stem cell transplantation from HLA-identical siblings after reduced-intensity conditioning with BU and FLU, ATG has no major impact on the rate of graft rejection and acute GVHD, but it reduces the incidence of limited chronic GVHD. Keywords: ATG; reduced intensity; busulfan; fludarabine; allogeneic stem cell transplantation Reduced-intensity conditioning regimens with busulfan (BU), fludarabine (FLU) and antithymocyte globulin (ATG) are increasingly used in related and unrelated hematopoietic stem cell transplantation (HSCT). 1 While the use of ATG as an additional drug for graftversus-host disease (GVHD) prophylaxis is widely accepted in unrelated transplantation, the application in HLA-identical sibling transplantation is a matter of debate. ATG-Fresenius is a polyclonal IgG antibody raised in rabbits against the Jurkat T cell line. 2 The antibody had been incorporated into dose-reduced conditioning regimens for two reasons: first, ATG given before transplantation exerts T-cell depletion of the recipient, which facilitates donor stem cell engraftment after nonmyeloablative doses of BU and FLU and second, antibody persisting in the recipient beyond transplantation exerts in vivo depletion of donor T cells, thereby possibly reducing the risk for acute and chronic GVHD. 3, 4 However, ATG has considerable short-term toxicity. 5 While the efficacy of ATG to prevent GVHD and to reduce nonrelapse mortality after myeloablative HSCT has been demonstrated in several studies, the role of ATG in reduced-intensity conditioning has not been evaluated. [6] [7] [8] [9] [10] However, reduced-intensity conditioning with BU and FLU was safe even without ATG in 24 patients as shown by our group.
11 In order to assess the impact of ATG, we retrospectively compared the engraftment, incidence and severity of GVHD and survival after BU-and FLU-based reduced-intensity conditioning with or without ATG in patients who had received peripheral blood stem cell transplantation (PBSCT) from HLAidentical siblings.
Patients and methods

Patient selection
Retrospectively, we collected the data of patients from six German transplant centers (Berlin, Hamburg, Dresden, Wiesbaden, Idar-Oberstein and Essen), who met the following inclusion criteria: (1) date of transplantation between January 1998 and April 2001; (2) HLA-identical sibling as donor; (3) dose-reduced conditioning with either BU 8 mg/kg and FLU 150 mg/m 2 (BU/FLU) or BU 8 mg/kg, FLU 180 mg/m 2 and ATG (Fresenius) 40 mg/kg (BU/FLU/ ATG) -the substitution of oral BU by an equivalent dose of an intravenous formulation was accepted; (4) G-CSF mobilized non-T-cell-depleted peripheral blood stem cells as graft; (5) GVHD prophylaxis with either CSA alone or in combination with 'short-course' methotrexate or mycophenolate mofetil; within this period of time, three transplant centers (Dresden, Idar-Oberstein and Wiesbaden) treated patients uniformly with BU/FLU, while the remaining centers (Hamburg, Berlin and Essen) used BU/ FLU/ATG as a conditioning regimen. Patient records of all eligible patients were re-evaluated for transplant data and follow-up.
Patient characteristics
In all, 83 patients were included in the analysis. Their median age was 52 years (range, 25-67 years). Diagnoses were acute myeloid leukemia (AML) (n ¼ 25), chronic myeloid leukemia (CML) (n ¼ 12), Hodgkin's disease (HD) or Non-Hodgkin's lymphoma (NHL) (n ¼ 25), myelodysplastic syndromes (MDS) and secondary AML (n ¼ 21). In total, 55% of patients were above 50 years, 17% had prior high-dose chemotherapy with autologous stem cell rescue, 14% had a history of an invasive fungal infection and 35% had significant comorbidity. A total of 38 patients received BU/FLU and 45 patients received BU/FLU/ATG. The distribution of patients' characteristics among the two treatment groups is shown in Table 1 . Patients in the BU/ FLU group were significantly older (median age 56 vs 46 years, P ¼ 0.02), received the intravenous formulation of BU more often (51 vs 24%, P ¼ 0.01) and less often suffered from lymphoma (47 vs 16%) and less often from acute leukemias (13 vs 44%) compared to the BU/FLU/ATG group (P ¼ 0.003).
Preparative regimens and transplantation
BU/FLU/ATG consisted of BU (1 mg/kg q.i.d. on days -6 and -5), FLU (30 mg/m 2 once daily on days -10 to -5) and rabbit ATG (10 mg/kg on days -4 to À1, Fresenius Hemocare, Germany), 1 and BU/FLU consisted of BU (1 mg/kg q.i.d. on days -3 and À2) and FLU (30 mg/m 2 once daily on days -6 to À2).
11 Granulocyte colonystimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC) were given on day 0. The median number of CD34-positive cells was 5.3 Â 10 6 CD34 þ cells/ kg (range, 1.7-16.8 Â 10 6 CD34 cells/kg). GVHD prophylaxis was carried out with CSA alone (n ¼ 32), CSA combined with short-course methotrexate (n ¼ 20) or CSA combined with MMF (n ¼ 31). The CSA levels were targeted towards the upper therapeutic range in the early post transplantation period. In standard-risk patients, CSA taper started on day þ 100 in the absence of GVHD and disease progression. Mycophenolate mofetil was given until day þ 30. Methotrexate 10 mg/m 2 was given on days þ 1, þ 3 and þ 6, respectively.
Supportive care and monitoring
Leukocyte-depleted red blood cell (RBC) transfusions were given to maintain a hemoglobin level of 8 g/dl and leukocyte-depleted single donor platelet concentrates were transfused to maintain a platelet count of 10 Â 10 9 /l in afebrile patients, and of 20 Â 10 9 /l in febrile patients. For infection, prophylaxis patients received oral quinolones and amphotericin B suspension starting with the beginning of the conditioning treatment. Empiric antibiotic treatment for neutropenic fever consisted of broad-spectrum antibiotics. Intravenous amphotericin B was added for refractory neutropenic fever or if fungal infection was suspected or documented. Prophylaxis against Pneumocystis carinii and Toxoplasma gondii was performed with trimethoprim-sulfamethoxazole until day þ 100. CMV monitoring was carried out at least weekly during the first 6 weeks, fortnightly during the first 3 months and subsequently monthly during the first half year. Five centers applied assays for the detection of CMV-antigen, while one center applied only a PCR-based method. Time schedules of CMV monitoring did not differ depending on the type of conditioning. No center applied prophylactic ganciclovir in patients at risk of CMV infection. The introduction of pre-emptive therapy was guided by CMVantigenemia or CMV-DNAemia. Chimerism analyses of whole-blood cell preparations were performed by different PCR techniques. Four centers applied a multiplex polymerase chain reaction technique using short tandem repeatmarkers, while two centers used allele-specific sequences or the Y chromosome in sex-mismatched transplantations.
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Definitions
Standard risk of relapse was defined as a diagnosis of CML in the first chronic phase, AML in first complete remission. High risk was defined as more advanced disease or any other diagnosis. Primary graft failure was diagnosed in patients who did not reach a neutrophil count of 0.5 Â 10 6 /l or a platelet count of 20 Â 10 9 /l or did not establish stable chimerism in the absence of progressive malignant disease in bone marrow or peripheral blood. Secondary graft failure was defined as persistent neutropenia o0.5 Â 10 6 /l and thrombocytopenia o20 Â 10 9 /l or decreasing donor chimerism in the absence of progressive disease after successful initial engraftment. Early progressive disease was defined as disease progression before day þ 100. Acute and chronic GVHD was graded according to consensus criteria. 15, 16 GVHD persisting beyond day þ 100 or de novo GVHD occurring after day þ 100 was classified as chronic GVHD. Nonrelapse mortality was defined as death not related to progression of the malignant disease.
Statistical analysis
The number of patients in each treatment group was sufficient to detect a difference of 20% in the incidence of acute GVHD grades II-IV with a power of more than 75% between the two cohorts. Comparisons of categorical variables between treatment groups were made by means of w 2 and Fisher's exact tests for small numbers. Differences between numerical variables were calculated by means of the Mann-Whitney U-test. A linear regression model was used for multivariate analysis of risk factors for increased RBC requirement. The probability of time-dependent events was estimated by the method of Kaplan and Meier. The influence of selected factors on survival estimates was analyzed with the log-rank test. Cox regression models were used for univariate and multivariate analyses of timedependent variables. Variables that had a P-value below 0.1 in univariate analysis were selected for multivariate analysis. In order to test for a potential influence of the type of conditioning on the occurrence of acute and chronic GVHD, a variable indicating the use of ATG or not was included into multivariate analysis regardless of its significance.
Results
Patient records of 83 patients were evaluated. Follow-up data were analyzed as of 01. 10.2002 . For all patients baseline information, details on conditioning, engraftment, GVHD, CMV infections and status at last follow-up were available. The median follow-up of living patients is 2 1/2 years.
Hematopoietic regeneration
Regeneration of leukocytes to 41 Â 10 6 /l after BU/FLU and BU/FLU/ATG took a median of 14 days (range, 0-35 days) and 16 days (range, 0-33 days). In univariate Cox /l were reached on day 10 (range, days 0-93) after conditioning BU/FLU, and on day 12.5 (range, days 0-50) after treatment with BU/FLU/ ATG. Five patients (n ¼ 3 after BU/FLU, n ¼ 2 after BU/ FLU/ATG) did not reach platelet counts of 420 Â 10 9 /l before they died due to septic multiorgan failure (n ¼ 2) or early relapse (n ¼ 3). Conditioning with BU/FLU compared to BU/FLU/ATG (P ¼ 0.017) and no use of MTX in GVHD prophylaxis (P ¼ 0.046) were associated with faster platelet engraftment in univariate Cox regression analysis. Other variables, such as the formulation of busulfan (P ¼ 0.122), the number of CD34-positive cells per kg (P ¼ 0.241) and recipient age (P ¼ 0.234), were statistically not significant. In multivariate Cox regression analysis, conditioning with BU/FLU/ATG compared to BU/FLU was confirmed as a risk factor for delayed platelet engraftment (P ¼ 0.043), while the type of GVHD prophylaxis failed significance (P ¼ 0.114). The median number of platelet apheresis concentrates transfused after BU/FLU vs BU/FLU/ATG were 2 U (range, 0-24) and 8 U (range, 0-34) (Po0.001), respectively. In total, 11 patients (24%) in the BU/FLU group and five patients (13%) in the BU/ FLU/ATG group did not need platelet support.
The median number of RBC units given after BU/FLU and BU/FLU/ATG was 6 (range, 0-23 U) and 10 (range, 0-24 U), respectively (P ¼ 0.002). Patients who had received MTX as GVHD prophylaxis needed more RBC support with a median number of 10 U (range 0-19) compared to 6 U (range 0-24) (P ¼ 0.058). RBC requirement was not increased in patients with ABO blood group-incompatible donors compared to patients with ABO-compatible donors (P ¼ 0.351). In a multivariate linear regression model, the type of conditioning (BU/FLU vs BU/FLU/ATG) was associated with the number of RBC requirement (P ¼ 0.011), while the use of MTX as GVHD prophylaxis was not statistically significant (P ¼ 0.254).
Transplant failure and early progressive disease
Secondary graft failure occurred in two patients (4%) who received BU/FLU compared to one primary graft failure (3%) and two secondary graft failures (5%) after BU/FLU/ ATG (P ¼ 0.66). The primary graft failure occurred in a 47-year-old patient with a high-grade NHL, who died from septic multiorgan failure on day þ 34. Secondary graft failure was presumably related to infections in four patients, caused by CMV in two patients, aspergillus in one and a perianal abscess in one patient. Three of these patients died on days þ 78, þ 90 and þ 92 after PBSCT from septic complications. One patient received a second transplant of the same donor after reconditioning on day þ 120. He is alive and well on day þ 846.
Early progressive disease or relapse until day þ 100 occurred in 11 patients after BU/FLU and in five patients after BU/FLU/ATG (P ¼ 0.27). Expectedly, the probability of relapse or progression was associated with high-risk disease compared to standard-risk disease (31% vs 3%; P ¼ 0.002, log-rank test). It was not associated with the type of conditioning (24% vs 11% after BU/FLU compared to BU/FLU/ATG; P ¼ 0.18, log-rank test).
Incidence of acute and chronic GVHD
After conditioning with BU/FLU compared to BU/FLU/ ATG acute GVHD, grades II-IV were observed in 46% vs 49% (P ¼ 0.77) and acute GVHD grades III-IV in 23% vs 13% (P ¼ 0.39) ( Table 2 ). The median onset of acute GVHD was on day þ 29 (range, day þ 8 to þ 89) compared to day þ 23 (range, day þ 11 to þ 89) after PBSCT (P ¼ 0.57). After pre-treatment with BU/FLU compared to BU/FLU/ATG, any degree of chronic GVHD was observed in 74% vs 46% of patients (P ¼ 0.02), while the incidence of extensive chronic GVHD was identical in both groups (23%) ( Table 3 ). The probabilities of acute GVHD grades II-IV and chronic GVHD are shown in Figure 1 .
Univariate and multivariate analysis using a Cox regression model was carried out in order to detect the confounding risk factors for acute and chronic GVHD. Female donor sex (relative risk (RR) 3.1, 95% CI 1.6-6.2) and CSA-monotherapy (RR 2.2, 95% CI 1.2-4.3) were found to be associated independently with a higher risk of acute GVHD grades II-IV (Table 4) . As for the incidence of limited or extensive chronic GVHD, we identified CSA monotherapy (RR 2.6, 95% CI 1.3-5.0; P ¼ 0.005) and conditioning with BU/FLU (RR 2.1, 95% CI 1.1-4.1) as independent risk factors ( Table 5) .
Incidence of CMV infections
CMV antigenemia occurred in 12 out of 45 patients (27%) after BU/FLU and in seven of 38 (18%) patients after BU/ FLU/ATG (P ¼ 0.37). Among serologically positive patients, known to be at high risk of CMV infection, the incidences were 11 of 27 (41%) seropositive patients after BU/FLU and six of 23 (26%) patients after BU/FLU/ATG (P ¼ 0.28). Regarding the influence of acute GVHD, we found CMV infections in four of 43 (9%) patients with acute GVHD grades 0-I and in 15 of 38 (39%) patients with acute GVHD grades II-IV (P ¼ 0.001). 
Survival analyses
With a median follow-up of 2 1/2 years (range, 1-4 years), 35 patients are alive and 48 patients have died. The causes of death were disease progression in 22 patients and treatment-related complications in 26 patients mostly related to GVHD. The outcome in patients who had received conditioning with BU/FLU or BU/FLU/ATG did not differ significantly with respect to overall survival (P ¼ 0.80, log-rank test), treatment-related mortality (P ¼ 0.59, log-rank test) and relapse mortality (P ¼ 0.83, log-rank test) (see Figure 2 ).
Discussion
The rationale to include ATG in reduced-intensity conditioning in HLA-identical sibling transplantation was to facilitate donor cell engraftment and to reduce the incidence and severity of GVHD. In order to assess the efficacy of ATG in this setting, we compared the outcome of PBSCT from HLA-identical siblings after reducedintensity conditioning with or without ATG. Patients who received BU/FLU compared to those receiving BU/FLU/ATG had a significantly faster platelet engraftment (P ¼ 0.017), as well as lower need of platelet support (2 vs 8 U, Po0.001) and RBC transfusions (6 vs 10 U, P ¼ 0.002). Thrombocytopenia and delayed regeneration of platelets after allogeneic stem cell transplantation are well-known side effects of ATG, as described by Bacigalupo et al 6 and Kro¨ger et al. 8 The higher consumption of RBC transfusions has not been reported before, but may be related to prolonged thrombocytopenia.
Graft rejection generally occurred rarely. No patient after BU/FLU and one patient after BU/FLU/ATG had a primary graft failure (not significant). Two patients experienced secondary graft failure in each treatment group. Although the power of a statistical analysis of these rare events in 83 patients is low, our data do not indicate that ATG is required to facilitate engraftment in HLA-identical sibling PBSCT after reduced-intensity conditioning.
The incidences of acute GVHD grades II-IV were 46% after BU/FLU and 49% after BU/FLU/ATG (not significant). However, we observed more limited chronic GVHD after BU/FLU compared to BU/FLU/ATG (77% vs 46%, P ¼ 0.02), while the incidence of extensive chronic GVHD was identical (23%) in both the groups. Despite the limitations of a retrospective analysis, our results are likely to be reliable since major risk factors of GVHD were equally balanced in the two groups. All patients had HLAidentical siblings as donors and received unmodified PBSC as graft. The type of ATG, its dose and time schedule of application were identical in all patients. There was heterogeneity with respect to age, underlying diagnosis, the use of different formulations of BU and the use of MTX or MMF as additional GVHD prophylaxis. However, multivariate analyses that included these potential confounders confirmed our results. Another critical point is that, although the use of ATG was the major difference between the two conditioning regimens, minor differences in the timing and the cumulative dose of FLU also existed. However, it is hardly conceivable that these differences affected the incidence of GVHD. Furthermore, the incidences of acute and chronic GVHD after conditioning with BU/FLU/ATG in HLA-identical sibling transplantation fit within published data. Similar to our results, Slavin et al 1 reported incidences of acute GVHD grades II-IV that ranged from 40 to 50% and of chronic GVHD in 55% of patients after conditioning with BU/FLU/ATG. days after transplantation probability probability Figure 1 Probabilities of GVHD. The probability of acute GVHD grades II-IV was 48% in both groups (P ¼ 0.72, log-rank test). For chronic GVHD, the probabilities were 73% after BU/FLU and 56% after BU/ FLU/ATG (P ¼ 0.09, log-rank test). In total, 21 patients were not evaluable due to primary graft failure (n ¼ 1) and death before hematopoietic regeneration (n ¼ 1), secondary graft failure (n ¼ 2) or death before day +100 (n ¼ 17). NS ¼ not significant.
In contrast, after myeloablative conditioning and cumulative doses of ATG (Fresenius) between 30 and 90 mg/kg, Zander et al 3 observed GVHD grades II-IV in only 20% of patients with matched related donors and in 39% of patients with unrelated donors. 7, 8 The reported incidences of chronic GVHD were 36% after matched related and 29% after unrelated donor transplantation. Accordingly, Finke et al 10 reported that with the use of ATG (Fresenius) at cumulative doses between 60 and 90 mg/kg in matched and even mismatched unrelated donor bone marrow transplantation, the cumulative incidence of acute GVHD grades II-IV was as low as 21%. Despite the fact that these data are not derived from prospective randomized trials, the favourable results of ATG in myeloablative conditioning contrast our findings of no proven efficacy of ATG to reduce the incidence of acute GVHD or extensive chronic GVHD. Although limited chronic GVHD occurred less often after BU/FLU/ATG, the effect of ATG as GVHD prophylaxis in this setting appeared to be small.
Probably, the differences can be explained by the lower dose of ATG applied in our study compared to the studies showing favourable results. GVHD prophylaxis by ATG is mediated by in vivo T-cell depletion of the graft, which is dependent on the amount of active antibody present in the recipient at transplantation. This is related to the cumulative dose and the time schedule of its administration. 2 Schleuning et al 18 compared the incidences of acute GVHD after unrelated bone marrow transplantation and found that patients with cumulative doses of ATG below 60 mg/ kg suffered from more acute GVHD grades III and IV compared to patients who had received higher doses of ATG. Mohty et al 19 reported an association between the incidence of acute GVHD and the dose of thymoglobulin (TG) (IMTIX-Sangstat, Lyon, France) ranging between 2.5 and 10 mg/kg infused during conditioning between day -4 and day -1 before HLA-identical sibling transplantation. Bacigalupo et al 6 discussed a dose-response relationship based on the comparison of two randomized trials evaluating 7.5 and 15 mg/kg TG (Sangstat, Lyon, France) vs no T-cell-depleting agent. A significant reduction of acute GVHD was observed after 15 mg/kg, but not after 7.5 mg/kg TG. However, the application of the last dose of TG was on day -1 in the 15 mg/kg trial and on day -2 in the 7.5 mg/kg trial. Therefore, the length of the interval between the last dose of TG and transplantation could also have had an impact. Evidence for the importance of the timing of TG comes from a study with a cumulative dose of only 4.5 mg/kg TG (Sangstat, Fremont, CA, USA). TG was applied in divided doses with a last dose given on day -1 or even on day 0 in matched related and unrelated transplantation and resulted in a rate of acute GVHD grades II-IV of about 20%. 20, 21 In conclusion, reduced-intensity conditioning with BU/ FLU in HLA-identical sibling transplants led to faster platelet engraftment and less transfusion support compared to conditioning with BU/FLU/ATG. Administration of ATG did not influence the rate of graft rejection. In our opinion, there is no evidence that ATG needs to be included in reduced-intensity conditioning in order to facilitate donor cell engraftment in HLA-identical sibling Table 4 Cox regression analysis of risk factors for acute GVHD grades II-IV transplantation. In this retrospective analysis, 10 mg/kg ATG applied on days -4 to -1 had no impact on acute GVHD grades II-IV and on extensive chronic GVHD, while we found a reduction of limited chronic GVHD. In view of cost-effectiveness and in the light of significant short-term toxicity, the impact of different doses and different timings of ATG on GVHD, relapse rate, survival and quality of life should be evaluated in prospective trials in HLA-identical sibling transplantation. BU/FLU compared to BU/FLU/ATG, the overall survival was 40 and 41% (P ¼ 0.80, log-rank test), treatment-related mortality was 42 and 33% (P ¼ 0.59, log-rank test), and relapse mortality was 31 and 39% (P ¼ 0.83, log-rank test), respectively.
